Exane Derivatives Neurocrine Biosciences Inc Transaction History

Exane Derivatives

$157 Million
Q2 2022

A detailed history of Exane Derivatives transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Exane Derivatives holds 1,084 shares of NBIX stock, worth $148,573. This represents 0.07% of its overall portfolio holdings.

Number of Shares

1,084

Previous 3 36033.33%

Holding current value

$148,573

Previous $0 Infinity%

% of portfolio

0.07%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 12, 2022	BUY	$75.79 - $100.07 $81,928 - $108,175	1,081 Added 36033.33%	1,084 $105,000
Q4 2020 Jan 27, 2021	SELL	$86.91 - $108.33 $3,824 - $4,766	-44 Reduced 93.62%	3 $0
Q4 2019 Jan 22, 2020	SELL	$86.8 - $118.57 $4,860 - $6,639	-56 Reduced 54.37%	47 $5,000
Q3 2019 Oct 15, 2019	SELL	$83.82 - $101.5 $419,099 - $507,500	-5,000 Reduced 97.98%	103 $9,000
Q2 2019 Jul 12, 2019	BUY	$72.24 - $91.27 $17,771 - $22,452	246 Added 5.06%	5,103 $0
Q1 2019 Apr 24, 2019	BUY	$69.31 - $91.53 $303,023 - $400,169	4,372 Added 901.44%	4,857 $0
Q4 2018 Jan 31, 2019	BUY	$68.32 - $124.36 $33,066 - $60,190	484 Added 48400.0%	485 $34,000
Q3 2018 Oct 24, 2018	SELL	$98.88 - $125.85 $98 - $125	-1 Reduced 50.0%	1 $0
Q2 2018 Jul 19, 2018	SELL	$75.3 - $105.99 $1,731 - $2,437	-23 Reduced 92.0%	2 $0
Q1 2018 Apr 30, 2018	SELL	$75.88 - $92.43 $10,623 - $12,940	-140 Reduced 84.85%	25 $0
Q4 2017 Jan 29, 2018	SELL	$58.53 - $77.59 $37,459 - $49,657	-640 Reduced 79.5%	165 $0
Q3 2017 Oct 18, 2017	BUY	$47.97 - $61.28 $38,615 - $49,330	805	805 $0

Others Institutions Holding NBIX

# of Institutions

626

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.

Account

Exane Derivatives Neurocrine Biosciences Inc Transaction History